吴德燕 男 博士，研究员

电子邮箱：wudeyan@hainanu.edu.cn

办公地址：太阳集团tyc5997（美安）13号楼341-2室

2014年6月博士毕业于华东理工大学药学院，2014年7月-2015年7月工作于上海睿智化学研究有限公司，2015年7月-2021年4月工作于中山大学药学院。2021年4月通过高层次人才引进到太阳集团tyc5997工作至今。

1.科研情况

“天然产物导向的创新药物发现”团队负责人，主要从事新药创制、靶向药物发现的产学研系列工作，团队通过发展高通量筛选技术与药物靶标发现技术，搭建基于中药资源提取物的样本库及药物筛选平台，开展活性成分研究、全合成研究、结构优化及成药性研究，并在此基础上开展基于多种疾病模型的药效研究、作用机制研究及临床前研究，发现其科学与市场价值。目前已在国内外重要学术刊物J. Med. Chem., Acta Pharm. Sin. B等发表论文30余篇；发明专利12项；主持国家自然科学基金面上项目、国家自然科学基金青年基金、广州市科技重点项目、海南省自然科学基金创新研究团队项目、海南省自然科学基金高层次人才项目等项目9项，科研经费超过500万元。

2.研究领域

天然产物导向的创新药物发现

药物分子设计、结构优化及作用机制研究

活性天然产物全合成、结构修饰及成药性研究

3.代表性科研项目

1) 国家自然科学基金面上项目，高选择性PDE5抑制剂的合理设计、结构优化及其抗肺纤维化作用研究，2024.01-2027.12，主持

2)国家自然科学基金面上项目，吡咯色原酮类PDE5特异性抑制剂的设计、抗肺动脉高压活性及作用机制研究，2019.01-2022.12，主持

3)国家自然科学基金青年基金项目，抗慢性阻塞性肺病PDE4高选择性抑制剂的发现:天然产物桑辛素M的结构优化及生物活性研究，2017.01-2019.12，主持

4)广州市科技重点项目，抗肺动脉高压I类创新化学药（PDE5抑制剂罗达那非）的临床前研究，2018.04-2021.03，主持

5)海南省自然科学基金创新研究团队项目，抗肺纤维化创新药物发现，2023.03-2026.02，主持

6)海南省自然科学基金高层次人才项目，磷酸二酯酶四型（PDE4）选择性抑制剂的合理设计与结构优化，2022.04-2025.03，主持

4.代表性论文

1) Sen Wang^#, Guofeng Yang^#, Kai Zhang, Zhexin Chen, Meiying Qiu, Siyu Hou, Tiansheng Zheng, Zongmin Wu, Qinjiang Ma, Furong Zhang, Ge Gao, Yi-You Huang, Qian Zhou*, Hai-Bin Luo*, Deyan Wu*. Structural optimization of Moracin M as novel selective phosphodiesterase 4 inhibitors for the treatment of idiopathic pulmonary fibrosis. Bioorg. Chem. 2024, 149, 107474.

2) Deyan Wu^#, Xuehua Zheng^#, Runduo Liu, Zhe Li, Zan Jiang, Qian Zhou, Yue Huang, Xu-Nian Wu, Chen Zhang, Yi-You Huang^*, Hai-Bin Luo^*. Free Energy Perturbation (FEP)-Guided Scaffold Hopping. Acta Pharm. Sin. B 2022, 12, 1351-1362.

3) Meiying Qiu^#, Deyan Wu^#, Yi-You Huang, Yue Huang, Qian Zhou, Yijing Tian, Lei Guo, Yuqi Gao*, Hai-Bin Luo*. Discovery of catalytic-site-fluorescent probes for tracing phosphodiesterase 5 in living cells. RSC Adv. 2021, 11, 31967.

4) Yi-You Huang^#, Yan-Fa Yu^#, Chen Zhang^#, Yiping Chen, Qian Zhou, Zhuoming Li, Sihang Zhou, Zhe Li, Lei Guo, Deyan Wu*, Yinuo Wu*, Hai-Bin Luo*. Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors. J. Med. Chem. 2019, 62, 3707-3721.

5) Deyan Wu^#, Yadan Huang^#, Yiping Chen^#, Yi-You Huang, Haiju Geng, Tianhua Zhang, Chen Zhang, Zhe Li, Lei Guo, Jianwen Chen, and Hai-Bin Luo*. Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure–Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension. J. Med. Chem. 2018, 61, 8468-8473. 封面论文

6) Deyan Wu^#, Tianhua Zhang^#, Yiping Chen, Yadan Huang, Haiju Geng, Yanfa Yu, Chen Zhang, Zengwei Lai, Yinuo Wu, Xiaolei Guo, Jianwen Chen,* Hai-Bin Luo*. Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.. J. Med. Chem. 2017, 60, 6622-6637. 封面论文

7) Yan-Fa Yu^#, Chen Zhang^#, Yi-You Huang^#, Sirui Zhang, Qian Zhou, Xiangmin Li, Zengwei Lai, Zhe Li, Yuqi Gao, Yinuo Wu, Lei Guo*, Deyan Wu*, Hai-Bin Luo. Discovery and Optimization of Chromone Derivatives as Novel Selective Phosphodiesterase 10 Inhibitors. ACS Chem. Neurosci. 2020, 11, 1058-1071.

8) Jinxuan Li^#, Jing-Yi Chen^#, Ya-Lin Deng, Qian Zhou, Yinuo Wu*, Deyan Wu*, Hai-Bin Luo. Structure-Based Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel PDE10 Inhibitors With Antioxidant Activities. Front. Chem. 2018, 6, 167.

9) Yinuo Wu, Zhe Li, Yi-You Huang, Deyan Wu, Hai-Bin Luo*. Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer’s Disease. J. Med. Chem. 2018, 61, 5467-5483.

10) Zhe Li^#, Xin Li^#, Yi-You Huang^#, Yaoxing Wu^#, Runduo Liu, Lingli Zhou, Yuxi Lin, Deyan Wu, Lei Zhang, Hao Liu, Ximing Xu, Kunqian Yu, Yuxia Zhang, Jun Cui*, Chang-Guo Zhan*, Xin Wang*, Hai-Bin Luo*. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs. PNAS 2020, 117, 27381-27387.

11) Senling Feng^#, Huifang Zhou^#, Deyan Wu, Dechong Zheng, Biao Qu, Ruiming Liu, Chen Zhang, Zhe Li, Ying Xie*, Hai-Bin Luo*. Nobiletin and its derivatives overcome multidrug resistance (MDR) in cancer: total synthesis and discovery of potent MDR reversal agents, Acta Pharm. Sin. B 2020, 10, 327-343.

12) Lu Liu, Deyan Wu, Shu Zheng, Tengfei Li, Xiangmin Li, Sinan Wang, Jian Li, Hao Li*, Wei Wang*. Synthesis of Highly Functionalized Chiral 3,3′-Disubstituted Oxindoles via an Organocatalytic Enantioselective Michael Addition of Nitroalkanes to Indolylidenecyanoacetates. Organic Lett. 2012, 14, 134-137.